secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0000950170-22-008944
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio in-licenses RLYB331 from Sanofi; Q1 net loss $14.5M, cash $161.4M
--------------------------------------------------------------------------

- Exclusive worldwide license from Sanofi for preclinical anti-MTP-2 antibody RLYB331; upfront $3M, up to $43M development & $150M commercial milestones.
- Q1 2022 net loss of $14.5M ($0.48 per share) vs. $13.3M ($0.60) in Q1 2021; R&D spend $7.6M, G&A $6.7M.
- Cash, equivalents & marketable securities $161.4M as of March 31, 2022.
- Phase 1b proof-of-concept study for RLYB212 (FNAIT) initiated; initial data expected in Q3 2022.
- Phase 1 study of RLYB116 (complement inhibitor) ongoing; single-dose data expected in H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000095017022008944/0000950170-22-008944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000095017022008944/rlyb-20220505.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer